MetaCap

Adagene (ADAG) vs OnKure Therapeutics (OKUR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

OnKure Therapeutics (OKUR) has outperformed Adagene (ADAG) over the past year, gaining 4.7% versus a loss of 2.2%. Over five years, ADAG leads with a -79.7% price change compared with -96.2% for OKUR. Adagene is the larger company by market cap ($118.2 million vs $111.2 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ADAG-2.22%OKUR+4.65%
+175%+73%-28%
Nov 21, 20251 yearNov 20, 2026
ADAG-81.97%OKUR-96.62%
+38%-33%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ADAG versus OKUR key metrics
MetricADAGOKUR
Share price$1.76$2.70
Market cap$118.17M$111.21M
1-day change-12.44%-2.17%
YTD return-6.88%-6.90%
1-year return-2.22%+4.65%
5-year return-79.75%-96.16%
EPS (TTM)$-0.37$-2.26
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$7.67M—
Revenue growth (YoY)+7332.76%—
Net income (latest FY)$-17.61M$-59.52M
Operating margin-279.48%—
Net margin-229.56%—
52-week high$4.85$5.38
52-week low$1.27$2.01
Distance from 52-week high-63.71%-49.81%
Analyst consensusnonenone
Avg. price target upside+463.07%+464.81%
Average volume348.81K335.78K
Shares outstanding67.14M40.50M
Employees12845
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Adagene

ADAG stock →

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees

About OnKure Therapeutics

OKUR stock →

OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 45 employees

ADAG vs OKUR FAQ

Which is bigger, Adagene or OnKure Therapeutics?

Adagene (ADAG) is larger, with a market capitalization of $118.17M compared with $111.21M for OnKure Therapeutics (OKUR).

Which stock has performed better over the past year, ADAG or OKUR?

OKUR returned +4.65% over the past 12 months, compared with -2.22% for ADAG (price return, excluding dividends). Past performance does not predict future results.

Are Adagene and OnKure Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons